Plain-English translation of NCT07511647 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called to see how well it works for treating moderate to severe plaque psoriasis. Researchers will compare it head-to-head with , which is already approved for this condition. The goal is to understand whether the new treatment is just as effective and safe as the existing option.
While there are treatments available for plaque psoriasis, doctors are always looking for new options that might work better, cause fewer side effects, or be more convenient for patients. This trial will help determine whether this medication could be a valuable choice for people living with this condition.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new or the approved medication. Neither you nor your doctor would know which treatment you're getting (this is called being 'blinded' and helps ensure fair results). You would attend visits to receive your injections and have your skin monitored to see how well the treatment is working and to check for any side effects.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Qilu Pharmaceutical Co., Ltd.
Enrollment target
~318 participants
Started
June 2026
Primary completion
December 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yu ling Shi, Doctor
Qilu Pharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.